bcax (BCAX) Analyst & Key Data

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

6

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$22.81

Median Target+25.30%

$28.58

Potential upside vs current price

DCF Value-92.98%

$1.60

Potential downside vs current price

Current Stock Price

$22.81

Median Target+25.30%

$28.58

Potential upside vs current price

DCF Value-92.98%

$1.60

Potential downside vs current price

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

6

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$22.81

Median Target+25.30%

$28.58

Potential upside vs current price

DCF Value-92.98%

$1.60

Potential downside vs current price

Current Stock Price

$22.81

Median Target+25.30%

$28.58

Potential upside vs current price

DCF Value-92.98%

$1.60

Potential downside vs current price

Bicara Therapeutics Inc. Common Stock